NeurologyLive® Brain Games: September 7, 2025

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy. Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease. This week's questions includes the theme of RNA therapeutics for neuromuscular disorders. Click here to check out the prior iterations of Brain Games. Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email: mmeglio@neurologylive.com. Which RNA therapeutic was the first antisense oligonucleotide approved for Duchenne muscular dystrophy (DMD) Risdiplam Eteplirsen Nusinersen Golodirsen Risdiplam, approved for spinal muscular atrophy (SMA), acts by: Enhancing SMN2 exon 7 inclusion Skipping dystrophin exons Inhibiting nonsense-mediated decay Delivering SMN1 gene via AAV In myotonic dystrophy type 1 (DM1), RNA-targeted therapies aim to reduce: Expanded CTG repeats in the DMPK gene Toxic RNA foci sequestering MBNL proteins SMN2 exon skipping Deficiency of sarcoglycan